Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Hematology
Disease Category: Hematological Disorders
Location: United States, WV

Clinical Trial Details

Overview

Research Study Summary

WVU11310-Once daily intravenous Busulfex as part of reduced toxicity conditioning for patients with relapsed/refractory Hodgkin and non-Hodgkin lymphomas undergoing allogeneic hematopoietic cell transplantation - A multicenter phase II study.

Purpose

Primary Objective: To assess 1-year progression free survival of patients with chemotherapy refractory Hodgkin and non-Hodgkin lymphomas undergoing reduced-toxicity conditioning with once daily Busulfex and fludarabine

To Learn more
Phase

2

Gender

Both Male and Female

Age

N/A

Overall Status

Recruiting

Facility Type

N/A

Contact

West Virginia University - Clinical Trials Research Unit
1637 Health Sciences South, PO Box 9260
Morgantown, WV 26506
Phone: 304-293-7374

View Map

CW ID: 169037

Date Last Changed: July 23, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.